SPARCSun Pharma Advanced Research Company Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 6716.8% YoY
- • Profit growth: 553.5% YoY
- • ROE: 276.9%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 6-month return: +24.7%
- • Bullish Engulfing signal (setup quality 64%)
Bull case
- • Revenue growth: 6716.8% YoY
- • Profit growth: 553.5% YoY
- • ROE: 276.9%
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.00%
- • RSI: 39
- • MACD: bearish
- • 1-month return: -12.5%
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Dividend yield: 0.00%
- • RSI: 39
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.47). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.